Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PAVmed (PAVM) Preferred Shares (2021 - 2025)

PAVmed (PAVM) has 5 years of Preferred Shares data on record, last reported at $20.5 million in Q3 2025.

  • For Q3 2025, Preferred Shares changed N/A year-over-year to $20.5 million; the TTM value through Sep 2025 reached $20.5 million, changed N/A, while the annual FY2024 figure was $3.3 million, 10.79% up from the prior year.
  • Preferred Shares reached $20.5 million in Q3 2025 per PAVM's latest filing, up from $3.5 million in the prior quarter.
  • Across five years, Preferred Shares topped out at $20.5 million in Q3 2025 and bottomed at $2.4 million in Q3 2021.
  • Average Preferred Shares over 5 years is $3.8 million, with a median of $2.8 million recorded in 2023.
  • The widest YoY moves for Preferred Shares: up 11.56% in 2022, down 3.9% in 2022.
  • A 5-year view of Preferred Shares shows it stood at $2.4 million in 2021, then grew by 11.41% to $2.7 million in 2022, then increased by 11.06% to $3.0 million in 2023, then rose by 10.79% to $3.3 million in 2024, then skyrocketed by 517.97% to $20.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Preferred Shares were $20.5 million in Q3 2025, $3.5 million in Q2 2025, and $3.4 million in Q1 2025.